A 2020 study demonstrated that ginsenoside compound K (CK) effectively inhibited the NF-κB, p38, and JNK MAPK pathways in an in vitro experiment using RAW264.7 macrophages, significantly altering foam cell metabolism and thereby influencing atherosclerosis progression [72]. The gene discussed is MAPK1; the disease is atherosclerosis.